RESUMEN

BACKGROUND: The authors of prior small studies raised the hypothesis that symptoms in veterans of the 1991 Gulf War, such as chronic diarrhea, dizziness, fatigue, and sexual dysfunction, are due to cholinergic autonomic dysfunction. OBJECTIVE: To perform a confirmatory test of this prestated hypothesis in a larger, representative sample of Gulf War veterans. DESIGN: Nested case-control study. SETTING: Clinical and Translational Research Center, University of Texas Southwestern Medical Center, Dallas. PARTICIPANTS: Representative samples of Gulf War veterans meeting a validated case definition of Gulf War illness with 3 variants (called syndromes 1-3) and a control group, all selected randomly from the US Military Health Survey. MAIN OUTCOME MEASURES: Validated domain scales from the Autonomic Symptom Profile questionnaire, the Composite Autonomic Severity Score, and high-frequency heart rate variability from a 24-hour electrocardiogram. RESULTS: The Autonomic Symptom Profile scales were significantly elevated in all 3 syndrome groups (P< .001), primarily due to elevation of the orthostatic intolerance, secretomotor, upper gastrointestinal dysmotility, sleep dysfunction, urinary, and autonomic diarrhea symptom domains. The Composite Autonomic Severity Score was also higher in the 3 syndrome groups (P= .045), especially in syndrome 2, primarily due to a significant reduction in sudomotor function as measured by the Quantitative Sudomotor Axon Reflex Test, most significantly in the foot; the score was intermediate in the ankle and upper leg and was nonsignificant in the arm, indicating a peripheral nerve length-related deficit. The normal increase in high-frequency heart rate variability at night was absent or blunted in all 3 syndrome groups (P< .001). CONCLUSION: Autonomic symptoms are associated with objective, predominantly cholinergic autonomic deficits in the population of Gulf War veterans.

Asunto(s)

Enfermedades del Sistema Nervioso Autónomo/diagnóstico , Enfermedades del Sistema Nervioso Autónomo/epidemiología , Síndrome del Golfo Pérsico/diagnóstico , Síndrome del Golfo Pérsico/epidemiología , Vigilancia de la Población/métodos , Veteranos , Adulto , Enfermedades del Sistema Nervioso Autónomo/psicología , Estudios de Casos y Controles , Neuronas Colinérgicas/patología , Femenino , Guerra del Golfo , Encuestas Epidemiológicas/métodos , Humanos , Masculino , Persona de Mediana Edad , Síndrome del Golfo Pérsico/psicología , Veteranos/psicología

RESUMEN

An exaggerated response to emotional stimuli is among the many symptoms widely reported by veterans of the 1991 Persian Gulf War. These symptomologies have been attributed to damage and dysfunction associated with deployment-related exposures. We collected event-related potential data from 22 veterans meeting Haley criteria for Gulf War (GW) Syndromes 1-3 and from 8 matched GW veteran controls, who were deployed but not symptomatic, while they performed a visual three-condition oddball task where images authenticated to be associated with the 1991 Persian Gulf War were the distractor stimuli. Hyperarousal reported by ill veterans was significantly greater than that by control veterans, but this was not paralleled by higher amplitude P3a in their ERP responses to GW-related distractor stimuli. Whereas previous studies of PTSD patients have shown higher amplitude P3b responses to target stimuli that are placed amid trauma-related nontarget stimuli, ill veterans in this study showed P3b amplitudes to target stimuli - placed amid GW-related nontarget stimuli - that were significantly lower than those of the control group. Hyperarousal scores reliably predicted P3b, but not P3a, amplitudes. Although many factors may contribute to P3b amplitude differences - most notably depression and poor sleep quality, symptoms that are prevalent in the GW syndrome groups - our findings in context of previous studies on this population are consistent with the contention that dysfunction in cholinergic and dopaminergic neurotransmitter systems, and in white matter and basal ganglia may be contributing to impairments in GW veterans.

Asunto(s)

Potenciales Evocados Visuales/fisiología , Síndrome del Golfo Pérsico/complicaciones , Agitación Psicomotora/diagnóstico , Agitación Psicomotora/etiología , Anciano , Análisis de Varianza , Mapeo Encefálico , Estudios de Casos y Controles , Electroencefalografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estimulación Luminosa , Tiempo de Reacción/fisiología , Índice de Severidad de la Enfermedad , Veteranos

RESUMEN

An exaggerated response to emotional stimuli is one of the several symptoms widely reported by veterans of the 1991 Persian Gulf War. Many have attributed these symptoms to post-war stress; others have attributed the symptoms to deployment-related exposures and associated damage to cholinergic, dopaminergic, and white matter systems. We collected event-related potential (ERP) data from 20 veterans meeting Haley criteria for Gulf War Syndromes 1-3 and from 8 matched Gulf War veteran controls, who were deployed but not symptomatic, while they performed an auditory three-condition oddball task with gunshot and lion roar sounds as the distractor stimuli. Reports of hyperarousal from the ill veterans were significantly greater than those from the control veterans; different ERP profiles emerged to account for their hyperarousability. Syndromes 2 and 3, who have previously shown brainstem abnormalities, show significantly stronger auditory P1 amplitudes, purported to indicate compromised cholinergic inhibitory gating in the reticular activating system. Syndromes 1 and 2, who have previously shown basal ganglia dysfunction, show significantly weaker P3a response to distractor stimuli, purported to indicate dysfunction of the dopaminergic contribution to their ability to inhibit distraction by irrelevant stimuli. All three syndrome groups showed an attenuated P3b to target stimuli, which could be secondary to both cholinergic and dopaminergic contributions or disruption of white matter integrity.

Asunto(s)

Potenciales Evocados/fisiología , Síndrome del Golfo Pérsico/complicaciones , Agitación Psicomotora/etiología , Trastornos por Estrés Postraumático/etiología , Estimulación Acústica , Adulto , Anciano , Análisis de Varianza , Estudios de Casos y Controles , Electroencefalografía , Humanos , Masculino , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica , Agitación Psicomotora/diagnóstico , Tiempo de Reacción/fisiología , Trastornos por Estrés Postraumático/diagnóstico , Veteranos

RESUMEN

Both the 17-item Hamilton Rating Scale for Depression (HRSD(17)) and 30-item Inventory of Depressive Symptomatology - Clinician-rated (IDS-C(30) ) contain a subscale that assesses anxious symptoms. We used classical test theory and item response theory methods to assess and compare the psychometric properties of the two anxiety subscales (HRSD(ANX) and IDS-C(ANX)) in a large sample (N = 3453) of outpatients with non-psychotic major depressive disorder in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Approximately 48% of evaluable participants had at least one concurrent anxiety disorder by the self-report Psychiatric Diagnostic Screening Questionnaire (PDSQ). The HRSD(ANX) and IDS-C(ANX) were highly correlated (r = 0.75) and both had moderate internal consistency given their limited number of items (HRSD(ANX) Cronbach's alpha = 0.48; IDS-C(ANX) Cronbach's alpha = 0.58). The optimal threshold for ascribing the presence/absence of anxious features was found at a total score of eight or nine for the HRSD(ANX) and seven or eight for the IDS-C(ANX) . It would seem beneficial to delete item 17 (loss of insight) from the HRSD(ANX) as it negatively correlated with the scale's total score. Both the HRSD(ANX) and IDS-C(ANX) subscales have acceptable psychometric properties and can be used to identify anxious features for clinical or research purposes.

Asunto(s)

Ansiedad/diagnóstico , Ansiedad/etiología , Depresión/complicaciones , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Adolescente , Adulto , Anciano , Antidepresivos/uso terapéutico , Ansiedad/epidemiología , Ansiedad/psicología , Ensayos Clínicos como Asunto , Depresión/tratamiento farmacológico , Depresión/epidemiología , Depresión/psicología , Femenino , Humanos , Masculino , Tamizaje Masivo , Persona de Mediana Edad , Pacientes Ambulatorios , Estudios Prospectivos , Psicometría , Encuestas y Cuestionarios , Adulto Joven

RESUMEN

PURPOSE: To determine, with arterial spin labeling (ASL) perfusion magnetic resonance (MR) imaging and physostigmine challenge, if abnormal hippocampal blood flow in ill Gulf War veterans persists 11 years after initial testing with single photon emission computed tomography and nearly 20 years after the 1991 Gulf War. MATERIALS AND METHODS: The local institutional review board approved this HIPAA-compliant study. Veterans were screened for contraindications and gave written informed consent before the study. In a semiblinded retrospective protocol, veterans in three Gulf War illness groups-syndrome 1 (impaired cognition), syndrome 2 (confusion-ataxia), and syndrome 3 (central neuropathic pain)-and a control group received intravenous infusions of saline in an initial session and physostigmine in a second session, 48 hours later. Each infusion was followed by measurement of hippocampal regional cerebral blood flow (rCBF) with pulsed ASL. A mixed-effects linear model adjusted for age was used to test for differences in rCBF after the cholinergic challenge across the four groups. RESULTS: Physostigmine significantly decreased hippocampal rCBF in control subjects (P < .0005) and veterans with syndrome 1 (P < .05) but significantly increased hippocampal rCBF in veterans with syndrome 2 (P < .005) and veterans with syndrome 3 (P < .002). The abnormal increase in rCBF was found to have progressed to the left hippocampus of the veterans with syndrome 2 and to both hippocampi of the veterans with syndrome 3. CONCLUSION: Chronic hippocampal perfusion dysfunction persists or worsens in veterans with certain Gulf War syndromes. ASL MR imaging examination of hippocampal rCBF in a cholinergic challenge experiment may be useful as a diagnostic test for this condition.

Asunto(s)

Hipocampo/irrigación sanguínea , Hipocampo/fisiopatología , Angiografía por Resonancia Magnética , Circulación Cerebrovascular , Inhibidores de la Colinesterasa , Guerra del Golfo , Humanos , Angiografía por Resonancia Magnética/métodos , Persona de Mediana Edad , Fisostigmina , Flujo Sanguíneo Regional , Estudios Retrospectivos , Estados Unidos , Salud de los Veteranos

RESUMEN

OBJECTIVE: Attrition from treatment in the short and long term for major depressive disorder (MDD) is clearly an adverse outcome. To assist in tailoring the delivery of interventions to specific patients to reduce attrition, this study reports the incidence, timing, and predictors of attrition from outpatient treatment in public mental health clinics. METHODS: Outpatients with psychotic and nonpsychotic MDD receiving measurement-based care in the Texas Medication Algorithm Project (N=179) were evaluated to determine timing and rates of attrition as well as baseline sociodemographic, clinical, and attitudinal predictors of attrition. RESULTS: Overall, 23% (42/179) of the patients left treatment by 6 months, and 47% (84/179) left by 12 months. Specific beliefs about the impact of medication, such as its perceived harmfulness, predicted attrition at both 6 and 12 months. Younger age (P=0.0004) and fewer side effects at baseline (P=0.0376) were associated with attrition at 6 months. Younger age (P=0.0013), better perceived physical functioning (P=0.0007), and more negative attitudes about psychiatric medications at baseline (P=0.0075) were associated with attrition at 12 months. CONCLUSIONS: Efforts to elicit attitudes about medications and tailoring educational and other retention interventions for patients with negative beliefs about antidepressants both when initiating a new medication and throughout treatment may reduce attrition. Particular focus on younger patients and those requiring frequent visits may be helpful.

Asunto(s)

Antidepresivos/uso terapéutico , Servicios Comunitarios de Salud Mental/estadística & datos numéricos , Trastorno Depresivo Mayor/tratamiento farmacológico , Pacientes Desistentes del Tratamiento/estadística & datos numéricos , Adulto , Factores de Edad , Antidepresivos/efectos adversos , Trastorno Depresivo Mayor/complicaciones , Trastorno Depresivo Mayor/psicología , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Pacientes Ambulatorios , Pacientes Desistentes del Tratamiento/psicología , Escalas de Valoración Psiquiátrica , Calidad de Vida/psicología , Factores Socioeconómicos , Texas , Factores de Tiempo , Resultado del Tratamiento

RESUMEN

OBJETIVO: Habitualmente, los médicos formulanpreguntas a los pacientes con trastorno depresivomayor (TDM) no psicótico sobre los antecedentesfamiliares de suicidio. Sin embargo, se desconoce silos pacientes con un familiar que consumó el suicidiodifieren de los que no.MÉTODO: Se reclutó a los pacientes para el ensayomulticéntrico STAR*D. En el periodo basal, sesolicitó a los pacientes que refirieran si algún familiaren primer grado había fallecido por suicidio. Seevaluaron las diferencias en las característicasdemográficas y clínicas de pacientes con y sinantecedentes familiares de suicidio.RESULTADOS: Entre los pacientes con antecedentesfamiliares de suicidio (142/4.001; 3,5%), fue másprobable identificar antecedentes familiares deTDM, trastorno bipolar o cualquier trastorno delhumor y trastorno familiar por consumo desustancias, pero no pensamientos suicidas,comparado con aquellos sin dichos antecedentes. Elgrupo con antecedentes de suicidio de un familiarmanifestó una visión más pesimista del futuro y elTDM se inició a una edad más temprana. No sedetectaron otras diferencias significativas en lossíntomas depresivos, gravedad, recurrencia, subtipodepresivo o función diaria.CONCLUSIONES: Los antecedentes de suicidioconsumado en un miembro de la familia se asociaroncon diferencias clínicas mínimas en la presentacióntransversal de pacientes ambulatorios con TDM. Laslimitaciones del presente estudio incluyen la ausenciade información sobre familiares que hubieranintentado suicidarse, al igual que la edad de losprobandos cuando falleció el miembro de la familia.Las evaluaciones STAR*D se limitaron a lasnecesarias para determinar el diagnóstico y larespuesta al tratamiento y no incluyeron unavariedad más amplia de medidas psicológicas

---

OBJECTIVE: Clinicians routinely ask patients withnon-psychotic major depressive disorder (MDD)about their family history of suicide. It is unknown,however, whether patients with a family member whocommitted suicide differ from those without such ahistory.METHODS: Patients were recruited for the STAR*Dmulticenter trial. At baseline, patients were asked toreport first-degree relatives who had died fromsuicide. Differences in demographic and clinicalfeatures for patients with and without a familyhistory of suicide were assessed.RESULTS: Patients with a family history of suicide(142/4001; 3.5%) were more likely to have a familyhistory of MDD, bipolar disorder, or any mooddisorder, and familial substance abuse disorder, butnot suicidal thoughts as compared to those withoutsuch a history. The group with familial suicide had amore pessimistic view of the future and an earlierage of onset of MDD. No other meaningfuldifferences were found in depressive symptoms,severity, recurrence, depressive subtype, or dailyfunction.CONCLUSIONS: A history of completed suicide in afamily member was associated with minimal clinicaldifferences in the crosssectional presentation ofoutpatients with MDD. Limitations of the studyinclude lack of information about family memberswho had attempted suicide and the age of theprobands when their family member died. STAR*Dassessments were limited to those needed to ascertaindiagnosis and treatment response and did not includea broader range of psychological measures

Asunto(s)

Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Trastorno Depresivo Mayor/complicaciones , Suicidio/tendencias , Factores de Riesgo , Comorbilidad , Trastorno Depresivo Mayor/epidemiología , Familia/psicología

RESUMEN

OBJECTIVE: This study examined the characteristics and outcomes of patients with major depressive disorder (MDD), with or without atypical features, who were treated with acute bilateral electroconvulsive therapy (ECT). METHOD: Analyses were conducted with 489 patients who met DSM-IV criteria for MDD. Subjects were identified as typical or atypical on the basis of the Structured Clinical Interview for DSM-IV obtained at baseline prior to ECT. Depression symptom severity was measured by the 24-item Hamilton Rating Scale for Depression (HAM-D(24)) and the 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR(30)). Remission was defined as at least a 60% decrease from baseline in HAM-D(24) score and a total score of 10 or below on the last 2 consecutive HAM-D(24) ratings. The randomized controlled trial was performed from 1997 to 2004. RESULTS: The typical (N = 453) and atypical (N = 36) groups differed in several sociodemographic and clinical variables including gender (p = .0071), age (p = .0005), treatment resistance (p = .0014), and age at first illness onset (p < .0001) and onset of current episode (p = .0008). Following an acute course of bilateral ECT, a considerable portion of both the typical (67.1%) and the atypical (80.6%) groups reached remission. The atypical group was 2.6 (95% CI = 1.1 to 6.2) times more likely to remit than the typical group after adjustment for age, psychosis, gender, clinical site, and depression severity based on the HAM-D(24). CONCLUSION: Acute ECT is an efficacious treatment for depressed patients with typical or atypical symptom features. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000375.

Asunto(s)

Trastorno Depresivo Mayor/terapia , Terapia Electroconvulsiva/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Áreas de Influencia de Salud , Trastorno Depresivo Mayor/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Escalas de Valoración Psiquiátrica , Factores de Tiempo , Resultado del Tratamiento

RESUMEN

OBJECTIVE: About half of outpatients with major depressive disorder also have clinically meaningful levels of anxiety. The authors conducted a secondary data analysis to compare antidepressant treatment outcomes for patients with anxious and nonanxious major depression in Levels 1 and 2 of the STAR*D study. METHOD: A total of 2,876 adult outpatients with major depressive disorder, enrolled from 18 primary and 23 psychiatric care sites, received citalopram in Level 1 of STAR*D. In Level 2, a total of 1,292 patients who did not remit with or tolerate citalopram were randomly assigned either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286). Treatment could last up to 14 weeks in each level. Patients were designated as having anxious depression if their anxiety/somatization factor score from the 17-item Hamilton Depression Rating Scale (HAM-D) was 7 or higher at baseline. Rates of remission and response as well as times to remission and response were compared between patients with anxious depression and those with nonanxious depression. RESULTS: In Level 1 of STAR*D, 53.2% of patients had anxious depression. Remission was significantly less likely and took longer to occur in these patients than in those with nonanxious depression. Ratings of side effect frequency, intensity, and burden, as well as the number of serious adverse events, were significantly greater in the anxious depression group. Similarly, in Level 2, patients with anxious depression fared significantly worse in both the switching and augmentation options. CONCLUSIONS: Anxious depression is associated with poorer acute outcomes than nonanxious depression following antidepressant treatment.

Asunto(s)

Atención Ambulatoria , Trastornos de Ansiedad/tratamiento farmacológico , Citalopram/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Adolescente , Adulto , Anciano , Antidepresivos/uso terapéutico , Trastornos de Ansiedad/diagnóstico , Trastornos de Ansiedad/epidemiología , Citalopram/efectos adversos , Comorbilidad , Ciclohexanoles/uso terapéutico , Preparaciones de Acción Retardada , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/epidemiología , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Estudios Prospectivos , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Trastornos Somatomorfos/diagnóstico , Trastornos Somatomorfos/tratamiento farmacológico , Trastornos Somatomorfos/epidemiología , Resultado del Tratamiento , Clorhidrato de Venlafaxina

RESUMEN

BACKGROUND: Clinicians routinely ask patients with non-psychotic major depressive disorder (MDD) about their family history of suicide. It is unknown, however, whether patients with a family member who committed suicide differ from those without such a history. METHODS: Patients were recruited for the STAR*D multicenter trial. At baseline, patients were asked to report first-degree relatives who had died from suicide. Differences in demographic and clinical features for patients with and without a family history of suicide were assessed. RESULTS: Patients with a family history of suicide (n=142/4001; 3.5%) were more likely to have a family history of MDD, bipolar disorder, or any mood disorder, and familial substance abuse disorder, but not suicidal thoughts as compared to those without such a history. The group with familial suicide had a more pessimistic view of the future and an earlier age of onset of MDD. No other meaningful differences were found in depressive symptoms, severity, recurrence, depressive subtype, or daily function. CONCLUSIONS: A history of completed suicide in a family member was associated with minimal clinical differences in the cross-sectional presentation of outpatients with MDD. Limitations of the study include lack of information about family members who had attempted suicide and the age of the probands when their family member died. STAR*D assessments were limited to those needed to ascertain diagnosis and treatment response and did not include a broader range of psychological measures.

Asunto(s)

Trastorno Bipolar/genética , Trastorno Depresivo Mayor/genética , Trastornos del Humor/genética , Suicidio/psicología , Adulto , Edad de Inicio , Antidepresivos de Segunda Generación/uso terapéutico , Trastorno Bipolar/diagnóstico , Trastorno Bipolar/psicología , Trastorno Bipolar/terapia , Citalopram/uso terapéutico , Terapia Cognitivo-Conductual , Terapia Combinada , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/psicología , Trastorno Depresivo Mayor/terapia , Femenino , Predisposición Genética a la Enfermedad/genética , Predisposición Genética a la Enfermedad/psicología , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Humor/diagnóstico , Trastornos del Humor/psicología , Trastornos del Humor/terapia , Recurrencia , Factores de Riesgo , Trastornos Relacionados con Sustancias/diagnóstico , Trastornos Relacionados con Sustancias/genética , Trastornos Relacionados con Sustancias/psicología , Intento de Suicidio/psicología , Resultado del Tratamiento

RESUMEN

BACKGROUND: The use of double-blind designs, normally the criterion standard of clinical trials, is impossible when comparing medication therapy to procedural therapies for depression. In the Consortium for Research in Electroconvulsive Therapy (CORE) trial, depressed patients recently remitted with electroconvulsive therapy (ECT) were randomly assigned to receive continuation therapy with either ECT or medications. The purpose of this article is to describe the design characteristics and challenges of the trial and of our method of dealing with the lack of double-blind outcome assessment. METHODS: The primary outcome measure was time to relapse of depression in the continuation phase. We developed a method to achieve partial blinding of depressive severity assessment. This consisted of videotaping the structured interviews, having the video tapes co-rated by personnel not involved in the patient's care, and a videotape-tracking maneuver so that the assessor of the videotapes could be blinded to phase and type of treatment. RESULTS: We enrolled 624 patients into the initial treatment phase of the trial. Of these, 201 met criteria for randomization into the second, continuation phase. Our videotape-tracking maneuver to reduce bias in outcome assessment worked well during the trial. CONCLUSIONS: The CORE study is the first multicenter, randomized controlled trial of continuation ECT in the relapse prevention of major depressive episodes. We successfully recruited a large number of severely depressed patients into a 6 month trial and used a method of reducing bias that might result from lack of blinding.

Asunto(s)

Antidepresivos/administración & dosificación , Trastorno Depresivo Mayor/terapia , Terapia Electroconvulsiva , Compuestos de Litio/administración & dosificación , Nortriptilina/administración & dosificación , Evaluación de Procesos y Resultados en Atención de Salud/estadística & datos numéricos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antidepresivos/efectos adversos , Sesgo , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/psicología , Terapia Electroconvulsiva/efectos adversos , Electroencefalografía/efectos de los fármacos , Femenino , Estudios de Seguimiento , Humanos , Entrevista Psicológica , Compuestos de Litio/efectos adversos , Cuidados a Largo Plazo , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Nortriptilina/efectos adversos , Calidad de Vida , Proyectos de Investigación , Retratamiento , Prevención Secundaria

RESUMEN

OBJECTIVE: The authors compared the effectiveness of cognitive therapy and pharmacotherapy as second-step strategies for outpatients with major depressive disorder who had received inadequate benefit from an initial trial of citalopram. Cognitive therapy was compared with medication augmentation and switch strategies. METHOD: An equipoise-stratified randomization strategy was used to assign participants to either augmentation of citalopram with cognitive therapy (N=65) or medication (N=117; either sustained-release bupropion [N=56] or buspirone [N=61]) or switch to cognitive therapy (N=36) or another antidepressant (N=86; sertraline [N=27], sustained-release bupropion [N=28], or extended-release venlafaxine [N=31]). Treatment outcomes and the frequency of adverse events were compared. RESULTS: Less than one-third of participants consented to randomization strata that permitted comparison of cognitive therapy and pharmacotherapy. Among participants who were assigned to second-step treatment, those who received cognitive therapy (either alone or in combination with citalopram) had similar response and remission rates to those assigned to medication strategies. For those who continued on citalopram, medication augmentation resulted in significantly more rapid remission than augmentation with cognitive therapy. Among those who discontinued citalopram, there were no significant differences in outcome, although those who switched to a different antidepressant reported significantly more side effects than those who received cognitive therapy alone. CONCLUSIONS: After an unsatisfactory response to citalopram, patients who consented to random assignment to either cognitive therapy or alternative pharmacologic strategies had generally comparable outcomes. Pharmacologic augmentation was more rapidly effective than cognitive therapy augmentation of citalopram, whereas switching to cognitive therapy was better tolerated than switching to a different antidepressant.

Asunto(s)

Citalopram/uso terapéutico , Terapia Cognitivo-Conductual , Trastorno Depresivo Mayor/terapia , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Adulto , Atención Ambulatoria , Antidepresivos/uso terapéutico , Bupropión/uso terapéutico , Buspirona/uso terapéutico , Terapia Combinada , Estudios Cruzados , Ciclohexanoles/uso terapéutico , Árboles de Decisión , Preparaciones de Acción Retardada , Trastorno Depresivo Mayor/psicología , Femenino , Humanos , Masculino , Agonistas de Receptores de Serotonina/uso terapéutico , Resultado del Tratamiento , Clorhidrato de Venlafaxina

RESUMEN

OBJECTIVE: Treatment of major depressive disorder typically entails implementing treatments in a stepwise fashion until a satisfactory outcome is achieved. This study sought to identify factors that affect patients' willingness to accept different second-step treatment approaches. METHOD: Participants in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial who had unsatisfactory outcomes after initial treatment with citalopram were eligible for a randomized second-step treatment trial. An equipoise-stratified design allowed participants to exclude or include specific treatment strategies. Analyses were conducted to identify factors associated with the acceptability of the following second-step treatments: cognitive therapy versus no cognitive therapy, any switch strategy versus any augmentation strategy (including cognitive therapy), and a medication switch strategy only versus a medication augmentation strategy only. RESULTS: Of the 1,439 participants who entered second-step treatment, 1% accepted all treatment strategies, 3% accepted only cognitive therapy, and 26% accepted cognitive therapy (thus, 71% did not accept cognitive therapy). Those with higher educational levels or a family history of a mood disorder were more likely to accept cognitive therapy. Participants in primary care settings and those who experienced a greater side effect burden or a lower reduction in symptom severity with citalopram were more likely to accept a switch strategy as compared with an augmentation strategy. Those with concurrent drug abuse and recurrent major depressive disorder were less likely to accept a switch strategy. CONCLUSIONS: Few participants accepted all treatments. Acceptance of cognitive therapy was primarily associated with sociodemographic characteristics, while acceptance of a treatment switch was associated with the results of the initial treatment.

Asunto(s)

Citalopram/uso terapéutico , Terapia Cognitivo-Conductual , Trastorno Depresivo Mayor/epidemiología , Trastorno Depresivo Mayor/terapia , Aceptación de la Atención de Salud , Adulto , Atención Ambulatoria , Protocolos Clínicos , Terapia Combinada , Estudios Cruzados , Trastorno Depresivo Mayor/tratamiento farmacológico , Escolaridad , Femenino , Humanos , Masculino , Atención Primaria de Salud/estadística & datos numéricos , Estudios Prospectivos , Recurrencia , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Índice de Severidad de la Enfermedad , Trastornos Relacionados con Sustancias/epidemiología , Resultado del Tratamiento

RESUMEN

INTRODUCTION: Clinicians routinely ask patients with major depressive disorder (MDD) about their family history. It is unknown, however, if patients who report a positive family history differ from those who do not. This study compared the demographic and clinical features of a large cohort of treatment-seeking outpatients with non-psychotic MDD who reported that they did or did not have at least one first-degree relative who had either MDD or bipolar disorder. METHODS: Subjects were recruited for the STAR( *)D multicenter trial. Differences in demographic and clinical features for patients with and without a family history of mood disorders were assessed after correcting for age, sex, race, and ethnicity. RESULTS: Patients with a family history of mood disorder (n=2265; 56.5%) were more frequently women and had an earlier age of onset of depression, as compared to those without such a history (n=1740; 43.5%). No meaningful differences were found in depressive symptoms, severity, recurrence, depressive subtype, or daily function. CONCLUSIONS: Women were twice as likely as men to report a positive family history of mood disorder, and a positive family history was associated with younger age of onset of MDD in the proband. Consistent with prior research, early age of onset appears to define a familial and, by extension, genetic subtype of major depressive disorder.

Asunto(s)

Trastorno Depresivo Mayor/epidemiología , Trastorno Depresivo Mayor/fisiopatología , Salud de la Familia , Trastornos del Humor , Adolescente , Adulto , Edad de Inicio , Anciano , Estudios de Cohortes , Demografía , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Humor/diagnóstico , Trastornos del Humor/epidemiología , Trastornos del Humor/genética , Pacientes Ambulatorios , Índice de Severidad de la Enfermedad , Factores Sexuales

RESUMEN

OBJECTIVE: The purpose of this study was to compare the effectiveness and tolerability of tranylcypromine and combination treatment with extended-release venlafaxine and mirtazapine in patients with treatment-resistant major depression whose current depressive episode had not responded adequately to treatment in three prior prospective medication trials. METHOD: Adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or had withdrawn from treatment because of intolerance in three previous prospective medication trials were randomly assigned to receive open-label treatment with either tranylcypromine (N=58) or extended-release venlafaxine plus mirtazapine (N=51). The primary outcome measure was whether patients achieved remission, which was defined as a score < or =7 at exit on the 17-item Hamilton Depression Rating Scale (HAM-D). The HAM-D was administered by telephone by raters to whom treatment was masked. RESULTS: Remission rates were not significantly different between the two treatment groups (6.9% for the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group). The mean daily dose at exit for tranylcypromine was 36.9 mg (SD=18.5); for venlafaxine, 210.3 mg (SD=95.2); and for mirtazapine, 35.7 mg (SD=17.6). Tranylcypromine was associated with significantly less symptom reduction and greater attrition due to intolerance. CONCLUSIONS: Remission rates were modest for both the tranylcypromine group and the extended-release venlafaxine plus mirtazapine group, and the rates were not statistically different between groups. The lower side effect burden, lack of dietary restrictions, and ease of use of venlafaxine and mirtazapine suggest that this combination may be preferred over tranylcypromine for patients with highly treatment-resistant depression who have not benefited adequately from several prior treatments.

Asunto(s)

Antidepresivos/uso terapéutico , Ciclohexanoles/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Mianserina/análogos & derivados , Tranilcipromina/uso terapéutico , Adulto , Antidepresivos/efectos adversos , Antidepresivos de Segunda Generación/uso terapéutico , Antidepresivos Tricíclicos/uso terapéutico , Preparaciones de Acción Retardada , Trastorno Depresivo Mayor/psicología , Esquema de Medicación , Resistencia a Medicamentos , Quimioterapia Combinada , Femenino , Humanos , Entrevistas como Asunto , Masculino , Mianserina/uso terapéutico , Persona de Mediana Edad , Mirtazapina , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Tranilcipromina/efectos adversos , Resultado del Tratamiento , Clorhidrato de Venlafaxina

RESUMEN

OBJECTIVE: This study evaluated the concordance between the self-report and the clinician-rated versions of the Inventory of Depressive Symptomatology (IDS-30) and between the two versions of the briefer 16-item Quick Inventory of Depressive Symptomatology (QIDS-16). METHODS: Data were gathered for 544 adult outpatients with psychotic (N = 106) or nonpsychotic (N = 438) major depressive disorder at 14 public sector mental health clinics in the Texas Medication Algorithm Project. Data for the QIDS-16 were extracted from the IDS-30. Baseline scores and scores from the final study visit at or before month 12 were analyzed. The clinician-rated and the self-report versions of each scale were compared in their identification of response to treatment and remission. RESULTS: The average baseline IDS-SR-30 total score was 2.2 points higher (indicating greater severity) than the IDS-C-30 score; the average QIDS-SR-16 total score was only .3 points higher than the QIDS-C-16 score. The IDS-SR-30 and the IDS-C-30, as well as the QIDS-C-16 and QIDS-SR-16, agreed substantially in classifying response and remission for patients, regardless of whether the patients had psychotic features. None of a large number of clinical and demographic features accounted for differences between the QIDS-SR-16 and QIDS-C-16 total scores. CONCLUSIONS: Either the IDS-30 or the QIDS-16 self-report adequately assesses depressive symptom severity among public-sector outpatients with major depressive disorder. The briefer QIDS-16 may be preferred to save time and cost.

Asunto(s)

Depresión/diagnóstico , Personal de Salud , Autorrevelación , Encuestas y Cuestionarios , Adulto , Demografía , Depresión/epidemiología , Depresión/psicología , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/epidemiología , Trastorno Depresivo Mayor/psicología , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Femenino , Humanos , Masculino , Variaciones Dependientes del Observador , Trastornos Psicóticos/diagnóstico , Trastornos Psicóticos/epidemiología , Trastornos Psicóticos/psicología , Índice de Severidad de la Enfermedad

RESUMEN

BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).

Asunto(s)

Antidepresivos de Segunda Generación/uso terapéutico , Bupropión/uso terapéutico , Ciclohexanoles/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Sertralina/uso terapéutico , Adulto , Antidepresivos de Segunda Generación/efectos adversos , Bupropión/efectos adversos , Ciclohexanoles/efectos adversos , Preparaciones de Acción Retardada , Femenino , Humanos , Masculino , Inducción de Remisión , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Sertralina/efectos adversos , Factores de Tiempo , Insuficiencia del Tratamiento , Clorhidrato de Venlafaxina

RESUMEN

BACKGROUND: Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach. METHODS: We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without remission despite a mean of 11.9 weeks of citalopram therapy (mean final dose, 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augmentation and 286 to receive buspirone (at a dose of up to 60 mg per day) as augmentation. The primary outcome of remission of symptoms was defined as a score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of this study; scores were obtained over the telephone by raters blinded to treatment assignment. The 16-item Quick Inventory of Depressive Symptomatology--Self-Report (QIDS-SR-16) was used to determine the secondary outcomes of remission (defined as a score of less than 6 at the end of this study) and response (a reduction in baseline scores of 50 percent or more). RESULTS: The sustained-release bupropion group and the buspirone group had similar rates of HRSD-17 remission (29.7 percent and 30.1 percent, respectively), QIDS-SR-16 remission (39.0 percent and 32.9 percent), and QIDS-SR-16 response (31.8 percent and 26.9 percent). Sustained-release bupropion, however, was associated with a greater reduction (from baseline to the end of this study) in QIDS-SR-16 scores than was buspirone (25.3 percent vs. 17.1 percent, P<0.04), a lower QIDS-SR-16 score at the end of this study (8.0 vs. 9.1, P<0.02), and a lower dropout rate due to intolerance (12.5 percent vs. 20.6 percent, P<0.009). CONCLUSIONS: Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings. Augmentation with sustained-release bupropion does have certain advantages, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events. (ClinicalTrials.gov number, NCT00021528.).

Asunto(s)

Bupropión/uso terapéutico , Buspirona/uso terapéutico , Citalopram/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Inhibidores de Captación de Dopamina/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Agonistas de Receptores de Serotonina/uso terapéutico , Adulto , Bupropión/administración & dosificación , Bupropión/efectos adversos , Buspirona/administración & dosificación , Buspirona/efectos adversos , Citalopram/administración & dosificación , Citalopram/efectos adversos , Preparaciones de Acción Retardada , Inhibidores de Captación de Dopamina/administración & dosificación , Inhibidores de Captación de Dopamina/efectos adversos , Esquema de Medicación , Quimioterapia Combinada , Femenino , Humanos , Modelos Logísticos , Masculino , Inducción de Remisión , Agonistas de Receptores de Serotonina/efectos adversos , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Insuficiencia del Tratamiento

RESUMEN

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial is a multi-site effectiveness study funded by the National Institute of Mental Health (NIMH) with the aim of identifying successful, acceptable and cost-effective treatment strategies for outpatients with unremitted depression. With enrollment of 4,041 adults with major depressive disorder (MDD), it is the largest controlled psychiatric treatment study ever undertaken. In the course of developing procedures to ensure that ambitious enrollment goals were met, a number of ethical and practical issues became apparent that underscore the conflicts between effectiveness research and human subject protections. These are delineated as they relate to study design; eligibility criteria; incentives to subjects; investigators and clinical sites; the complementary roles of clinical research coordinators (CRCs) and study clinicians; and recruitment and consent procedures. The STAR*D trial exemplifies the interplay and tension between those strategies that integrate research and clinical aims and roles in the service of enhancing external validity, site participation, and recruitment and retention versus those strategies that differentiate research and clinical treatment in the service of research integrity and human subject protections. We hope that a discussion of these key challenges and dilemmas and how they have been addressed will help inform future discussions concerning design and conduct of ethical effectiveness trials designed to optimize care in real world clinical settings.

Asunto(s)

Antidepresivos/uso terapéutico , Terapia Cognitivo-Conductual/ética , Terapia Cognitivo-Conductual/métodos , Trastorno Depresivo Mayor/terapia , Ética Clínica , Adolescente , Adulto , Anciano , Terapia Combinada , Trastorno Depresivo Mayor/tratamiento farmacológico , Trastorno Depresivo Mayor/economía , Femenino , Humanos , Masculino , Persona de Mediana Edad

RESUMEN

OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression, but the rates, timing, and baseline predictors of remission in "real world" patients are not established. The authors' primary objectives in this study were to evaluate the effectiveness of citalopram, an SSRI, using measurement-based care in actual practice, and to identify predictors of symptom remission in outpatients with major depressive disorder. METHOD: This clinical study included outpatients with major depressive disorder who were treated in 23 psychiatric and 18 primary care "real world" settings. The patients received flexible doses of citalopram prescribed by clinicians for up to 14 weeks. The clinicians were assisted by a clinical research coordinator in the application of measurement-based care, which included the routine measurement of symptoms and side effects at each treatment visit and the use of a treatment manual that described when and how to modify medication doses based on these measures. Remission was defined as an exit score of or=50% in baseline QIDS-SR score. RESULTS: Nearly 80% of the 2,876 outpatients in the analyzed sample had chronic or recurrent major depression; most also had a number of comorbid general medical and psychiatric conditions. The mean exit citalopram dose was 41.8 mg/day. Remission rates were 28% (HAM-D) and 33% (QIDS-SR). The response rate was 47% (QIDS-SR). Patients in primary and psychiatric care settings did not differ in remission or response rates. A substantial portion of participants who achieved either response or remission at study exit did so at or after 8 weeks of treatment. Participants who were Caucasian, female, employed, or had higher levels of education or income had higher HAM-D remission rates; longer index episodes, more concurrent psychiatric disorders (especially anxiety disorders or drug abuse), more general medical disorders, and lower baseline function and quality of life were associated with lower HAM-D remission rates. CONCLUSIONS: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials. The systematic use of easily implemented measurement-based care procedures may have assisted in achieving these results.

Asunto(s)

Citalopram/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Adolescente , Atención Ambulatoria , Enfermedad Crónica , Comorbilidad , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/epidemiología , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Masculino , Trastornos Mentales/epidemiología , Persona de Mediana Edad , Inventario de Personalidad , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Prevención Secundaria , Resultado del Tratamiento